Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma

Drug Development Research(2022)10.1002/ddr.22012Source: DataRank Database

Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma is a research paper published in Drug Development Research (2022). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.14)OA: greenTopics (29)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Dan Feng ORCID,Yashpal S. Chhonker ORCID,Michelle L. Varney ORCID,Jacob T. Williams,Lynette M. Smith ORCID

Live enrichment

PubMed:36433690 PMC:PMC9931648 OpenAlex:https://openalex.org/W4310022409

National Institutes of Health

Grant: P30CA036727

FWCI

1.14

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9931648

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.22012

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/ddr.22012

publisherhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.22012

Fields of Study

Cancer, Hypoxia, and MetabolismUbiquitin and proteasome pathwaysBiochemical and Molecular ResearchMedicine

MeSH Terms

AnimalsBone NeoplasmsDiterpenesPolyisoprenyl PhosphatesDiphosphatesSarcoma, EwingOsteosarcomaTerpenesFarnesyltranstransferaseMice

Keywords

GeranylgeranylationRabPrenylationGeranylgeranyl pyrophosphateBiologyFarnesyl pyrophosphateCancer researchGTPaseCell biologyBiochemistryATP synthaseEnzymeOsteosarcomaEwing SarcomaIsoprenoid Biosynthesis Pathway

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma

10.6084/m9.figshare.24979588.v1figshare

Additional file 1 of Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma

10.6084/m9.figshare.24979588figshare